ADMA Biologics, Inc. (ADMA) is a bio-pharmaceutical organization dedicated to manufacturing, developing and marketing specialized plasma-derived biologics for the treatment of immune deficiencies and the prevention of specified infectious diseases. The company was founded in 2004 and has its headquarters based in Ramsey, New Jersey, United States. ADMA Biologics' mission is to improve the health and quality of life of patients suffering from immunological disorders.
ADMA's extensive product portfolio includes some FDA-approved immunoglobulin products for patients facing immune system challenges. ADMA's flagship product BIVIGAM® is an intravenous immune globulin which was accepted by the U.S. Food and Drug Administration (FDA) in 2019 for patients with primary humoral immunodeficiency (PIDD).
This serious and chronic disease involves weakening of the immune system, causing susceptibility to infections. Another significant product from the company is ASCENIV™, an intravenous immune globulin for treating PIDD patients. Notably, ADMA also offers NABI-HB®, useful in protecting against Hepatitis B infections.
ADMA owns and operates three FDA-approved plasma collection centers under the ADMA BioCenters brand. These centers contribute to enhancing the company's control over plasma supply, a crucial raw material for its products. In addition to its own plasma collection, ADMA also maintains strategic relationships with third-party suppliers.
The company also operates its ImmunoTek plasma collection facilities, which provide high-quality plasma that is processed into life-saving immunoglobulin and other plasma-derived products. ADMA's commitment to plasma collection supports the industry's overall safety and supply chain by ensuring continued availability of this critical resource.
What sets ADMA Biologics apart is its high-value platform of plasma assets and immunoglobulin therapy, which helps in maintaining, restoring, and enhancing the health of patients. Moreover, the executives at ADMA possess extensive experience in plasma and immunoglobulin science and commercialization, thus allowing the company to continuously contribute to scientific advancement in the field.
Alongside capturing opportunities in the US market, ADMA Biologics is keen to expand its products' global presence. It believes that its comprehensive patient-centric approach, which commands a strong balance between innovative biologics and traditional patient care, will aid in providing personalized treatment solutions to a larger consumer base worldwide.
In terms of commitment to research and development, ADMA continues to invest heavily in expanding its clinical indications and advancing the plasma-processing sector. The company’s ethos embraces a steadfast approach to innovation, consumer safety, and health care cost containment that contributes to a sustainable healthcare system.
Overall, ADMA Biologics, Inc. remains a trusted provider in the healthcare industry, continuously striving to explore and implement therapeutic possibilities to aid the fight against immune deficiencies and infectious diseases around the globe.